CANbridge ×
Edit

CANbridge ×

http://www.canbridgepharma.com/
Last activity: 15.09.2026
Active
Categories: BioTechDevelopmentHealthTechLifeMedTechProductSpecialty
CANbridge is a biotechnology company focused on developing and commercializing rare disease therapeutics in China.
Website visits
8K /mo.
Mentions
21
Location: China, Beijing
Employees: 11-50
Total raised: $176M
Founded date: 2012
Email

Investors 5

Funding Rounds 4

DateSeriesAmountInvestors
05.12.2020Series E$43M-
18.02.2020Series D$98MGeneral At...
23.05.2017Series B$25M-
02.12.2014Series A$10M-

Mentions in press and media 21

DateTitleDescription
15.09.2026Gaucher Disease Drugs Market to Reach $4.3 Billion by 2036 as Long-Term Treatment and New Type 3 Therapies Reshape Rare-Disease CareEnzyme replacement therapy leads with 58% share while Type 1 Gaucher disease accounts for 67% of 2026 demand ROCKVILLE, Md., September 15, 2026 — The Gaucher disease treatment landscape is entering a new phase as established enzyme replacem...
29.04.2026WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare AccessContributing to the United Nations Sustainable Development Goals, driving equitable access to healthcare through technology and innovation Enhancing governance transparency and effectiveness to create long-term value for all stakeholders Em...
13.08.2025China’s CANbridge Soars on USD12.7 Million Baheal Deal That May Boost Rare-Disease Drug Sales(Yicai) Aug. 13 -- Shares in CANbridge Pharmaceuticals surged as much as 37.7 percent today after the Chinese rare-disease drug developer said pharmaceutical distributor Qingdao Baheal Medical will inject HKD100 million (USD12.7 million) in...
16.10.2023CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in ChinaBEIJING and BURLINGTON, Mass., Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transform...
09.10.2023CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)LIVMARLI is the First and Only Treatment Approved in Taiwan for Cholestatic Pruritus in ALGS LIVMARLI is approved for Cholestatic Pruritus in ALGS in the US, Canada, Europe, Mainland China, and other regions globally BEIJING and BURLINGTON,...
06.09.2023CANbridge to Participate in Two Investor Conferences in SeptemberBEIJING and BURLINGTON, Mass., Sept. 6, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transfo...
31.08.2023CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023BEIJING and CAMBRIDGE, Mass., Aug. 31, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals, Inc. ("CANbridge," stock code 1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development ...
25.02.2021CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle ArbitrationBEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 25, 2021-- CANbridge Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing drug candidates in China and North Asia, and Puma Biotechnology, Inc. (Na...
05.12.2020CANbridge Pharmaceuticals Completes $43 Million Series E Financing-
01.12.2020CANbridge Pharmaceuticals Closes $43 Million Series E FinancingBEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals Inc., a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers, announced that it has completed a US$43 million Series E...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In